Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 TrialYuqin Song, Xin Du, Yue-Rong Shuang et al.|Advances in Therapy|2021Cited by 19
A Novel Prognostic Index for Sporadic Burkitt Lymphoma in Adult Patients: A Real-Word Multicenter StudyMeiting Chen, Tongyu Lin, Fei Pan et al.|Research Square|2021Cited by 2